The PGY2 infectious diseases pharmacy residency at the University of Pittsburgh Medical Center (UPMC) Presbyterian University Hospital is designed for the individual who is interested in developing specialized clinical skills in the area of infectious diseases pharmacotherapy and antimicrobial stewardship. The resident will gain expertise in many aspects of infectious diseases pharmacotherapy including the interpretation of microbiological culture and susceptibility data; antimicrobial pharmacokinetics and pharmacodynamics; antimicrobial therapy in both the general and specialized patient populations; antimicrobial stewardship; and research.
The resident will work in close collaboration with infectious diseases pharmacists and physicians in the institution's established multidisciplinary antimicrobial stewardship program. The resident will participate in both didactic and experiential teaching as an adjunct instructor and preceptor at the University of Pittsburgh School of Pharmacy. The education of students and other healthcare professionals is an integral component of this residency. Additionally, the resident will have the opportunity to participate in the Mastery of Teaching Program at the School of Pharmacy. The resident will complete an infectious diseases focused research project through participation in a mentored residency research training program. This resulting work will be suitable for presentation and publication. Many opportunities to present formal seminars, patient cases, journal clubs, and in-service education for UPMC staff occur throughout the year. Flexibility is provided to meet the individual resident's goals and objectives.
Program objectives include:
Optimize the outcomes of patients with infectious diseases by providing evidence-based, patient-centered medication therapy as a multidisciplinary member of the antimicrobial stewardship program
As an authoritative expert on the use of medications in the care of patients with acute and chronic infectious diseases
Demonstrate professionalism and effective written and verbal communication skills in all components of pharmacy practice
Optimize pharmacotherapy and safe medication practices
Provide effective education to healthcare professionals
All residents must be eligible for pharmacist licensure in the Commonwealth of Pennsylvania. Applications for Pharmacist License and Intern Registration are available.
Eligible candidates will have completed an ASHP accredited PGY1 pharmacy residency program and must submit the standard application requirements via PhORCAS by December 31st. An on-site interview is required.
This residency site agrees that no person at this site will solicit, accept, or use any ranking related information from any residency candidate.
To prepare pharmacists to assume any of the following roles:
Antibiotic Stewardship Director/Pharmacist
Duration: 12 months
Number Positions: 1
Starting Date: July 1
Benefits: Health, dental, eye care, life, and disability available, vacation and professional travel provided, travel stipend available
Training Site Type: Hospital
Model (type): Teaching, tertiary
Professional Staff: 48
Total Beds: 1093
General Infectious Disease Consult Service
Antibiotic Stewardship Program
Clinical Microbiology Laboratory
Outpatient HIV Clinic
Antibiotic Stewardship Program
Transplant Infectious Diseases
Medical Intensive Care Unit
Surgical Infectious Diseases
Brian A. Potoski, PharmD BCPS (AQ-ID) (director)
UPMC is the premier health system in western Pennsylvania and one of the most renowned academic medical centers in the United States. The health system consists of tertiary, specialty and community hospitals, physician offices, and rehabilitation facilities. By integrating the resources of the University of Pittsburgh School of Pharmacy and UPMC, this residency program offers a challenging yet flexible environment where pharmacy residents learn to provide safe and effective, evidenced-based infectious diseases pharmacotherapy to individual patients.
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. Jim H, Wang T, Falcione BA, Olsen KM, Chen K, Tang H, Hui J, Zhai S. J Antimicrob Chemother. 2016;71:1772-85.
Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. Buehrle DJ, Shields RK, Clarke LG, Potoski BA, Clancy CJ, Nguyen MH. Antimicrob Agents Chemother. 2016;27:61.
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. Clin Infect Dis 2016;63:1615-18.
Dosing Practices of Intravenous Acyclovir for Herpes Encephalitis in Obesity: Results of a Pharmacist Survey. Wong A, Pickering AJ, Potoski BA. J Pharm Pract. 2017;30:324-8.
"A prospective, observational study evaluating the real-world use of bezlotoxumab and performance of institution specific criteria in preventing recurrence in patients treated for C. difficile disease with standard of care plus bezlotoxumab at an academic teaching hospital." Competitive Investigator-Initiated Study, Merck Pharmaceuticals. $54,000. Study period, 2017-2018.